The faster patients can be diagnosed with multiple sclerosis, the sooner they can begin taking the powerful medications that ...

Lupin receives USFDA approval for generic Siponimod Tablets to treat multiple sclerosis, boosting market presence and ...

Lynk received the green light from the FDA to begin clinical trials of its investigational oral therapy LNK01006 for MS and other diseases.

Roche Holdings AG (OTC:RHHBY) on Friday announced new 96-week data for fenebrutinib demonstrating that patients with relapsing multiple sclerosis (RMS) maintained no disability progression and low ...

Thousands of Australians battling a debilitating form of multiple sclerosis have been granted a reprieve, as a groundbreaking ...

Clinicians and health system leaders met in Portland, Oregon, on October 21, 2025, to discuss the evolving options for treating Alzheimer disease and multiple sclerosis.

BARCELONA, Spain — Annual dosing of rituximab for relapsing-remitting multiple sclerosis (RRMS) was noninferior to the typical dosing schedule of once every 6 months, which could offer a more ...

Nearly 80% of US neurologists prescribing drugs for multiple sclerosis (MS) received at least one pharma industry payment, with higher volume prescribers more likely to be beneficiaries, finds a 5 ...

What are called autoimmune diseases can affect just about every part of the body — even the brain — and tens of millions of ...